107 related articles for article (PubMed ID: 11072153)
21. Outcome of postmastectomy radiotherapy after primary systemic treatment in patients with clinical T1-2N1 breast cancer.
Cao L; Ou D; Shen KW; Cai G; Cai R; Xu F; Zhao SG; Xu C; Grellier Adedjouma N; Kirova YM; Chen JY
Cancer Radiother; 2018 Feb; 22(1):38-44. PubMed ID: 29306555
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness analysis of intraoperative radiation therapy for early-stage breast cancer.
Alvarado MD; Mohan AJ; Esserman LJ; Park CC; Harrison BL; Howe RJ; Thorsen C; Ozanne EM
Ann Surg Oncol; 2013 Sep; 20(9):2873-80. PubMed ID: 23812769
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness of zoledronic acid plus endocrine therapy in premenopausal women with hormone-responsive early breast cancer.
Delea TE; Taneja C; Sofrygin O; Kaura S; Gnant M
Clin Breast Cancer; 2010 Aug; 10(4):267-74. PubMed ID: 20705558
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness of letrozole in the extended adjuvant treatment of women with early breast cancer.
El Ouagari K; Karnon J; Delea T; Talbot W; Brandman J
Breast Cancer Res Treat; 2007 Jan; 101(1):37-49. PubMed ID: 16821085
[TBL] [Abstract][Full Text] [Related]
25. Updates in Postmastectomy Radiation.
Wright JL; Parekh A
Surg Oncol Clin N Am; 2017 Jul; 26(3):383-392. PubMed ID: 28576178
[TBL] [Abstract][Full Text] [Related]
26. [Cost-effectiveness of trastuzumab in the treatment of early stages breast cancer patients, in Portugal].
Macedo A; Monteiro I; Andrade S; Cirrincione A; Ray J
Acta Med Port; 2010; 23(3):475-82. PubMed ID: 20654267
[TBL] [Abstract][Full Text] [Related]
27. Cost-utility of the 21-gene recurrence score assay in node-negative and node-positive breast cancer.
Lamond NW; Skedgel C; Rayson D; Lethbridge L; Younis T
Breast Cancer Res Treat; 2012 Jun; 133(3):1115-23. PubMed ID: 22361999
[TBL] [Abstract][Full Text] [Related]
28. Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial.
Mittmann N; Au HJ; Tu D; O'Callaghan CJ; Isogai PK; Karapetis CS; Zalcberg JR; Evans WK; Moore MJ; Siddiqui J; Findlay B; Colwell B; Simes J; Gibbs P; Links M; Tebbutt NC; Jonker DJ; ;
J Natl Cancer Inst; 2009 Sep; 101(17):1182-92. PubMed ID: 19666851
[TBL] [Abstract][Full Text] [Related]
29. Selecting breast cancer patients with T1-T2 tumors and one to three positive axillary nodes at high postmastectomy locoregional recurrence risk for adjuvant radiotherapy.
Truong PT; Olivotto IA; Kader HA; Panades M; Speers CH; Berthelet E
Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1337-47. PubMed ID: 15817335
[TBL] [Abstract][Full Text] [Related]
30. Partial-breast irradiation versus whole-breast irradiation for early-stage breast cancer: a cost-effectiveness analysis.
Sher DJ; Wittenberg E; Suh WW; Taghian AG; Punglia RS
Int J Radiat Oncol Biol Phys; 2009 Jun; 74(2):440-6. PubMed ID: 18963542
[TBL] [Abstract][Full Text] [Related]
31. Breast cancer: systemic benefit of locoregional treatment.
Lawrence G; Castro P; Collins B
J Clin Oncol; 1996 Apr; 14(4):1403-4. PubMed ID: 8648401
[No Abstract] [Full Text] [Related]
32. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective.
Delea TE; El-Ouagari K; Karnon J; Sofrygin O
Breast Cancer Res Treat; 2008 Apr; 108(3):375-87. PubMed ID: 17653859
[TBL] [Abstract][Full Text] [Related]
33. Omission of Breast Radiotherapy in Low-risk Luminal A Breast Cancer: Impact on Health Care Costs.
Han K; Yap ML; Yong JH; Mittmann N; Hoch JS; Fyles AW; Warde P; Gutierrez E; Lymberiou T; Foxcroft S; Liu FF
Clin Oncol (R Coll Radiol); 2016 Sep; 28(9):587-93. PubMed ID: 27139262
[TBL] [Abstract][Full Text] [Related]
34. Surgery for degenerative cervical myelopathy: a patient-centered quality of life and health economic evaluation.
Witiw CD; Tetreault LA; Smieliauskas F; Kopjar B; Massicotte EM; Fehlings MG
Spine J; 2017 Jan; 17(1):15-25. PubMed ID: 27793760
[TBL] [Abstract][Full Text] [Related]
35. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial.
Overgaard M; Hansen PS; Overgaard J; Rose C; Andersson M; Bach F; Kjaer M; Gadeberg CC; Mouridsen HT; Jensen MB; Zedeler K
N Engl J Med; 1997 Oct; 337(14):949-55. PubMed ID: 9395428
[TBL] [Abstract][Full Text] [Related]
36. Postmastectomy radiotherapy in intermediate risk stage I-II breast cancer patients.
Mladenovic J; Susnjar S; Gavrilovic D; Borojevic N
J BUON; 2007; 12(2):215-20. PubMed ID: 17600875
[TBL] [Abstract][Full Text] [Related]
37. Economic evaluation of radiotherapy for early breast cancer after breast-conserving surgery in a health resource-limited setting.
Bai Y; Ye M; Cao H; Ma X; Xu Y; Wu B
Breast Cancer Res Treat; 2012 Nov; 136(2):547-57. PubMed ID: 23053654
[TBL] [Abstract][Full Text] [Related]
38. Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer by Age and Hormone Receptor Status: A Cost-Utility Analysis.
Leung W; Kvizhinadze G; Nair N; Blakely T
PLoS Med; 2016 Aug; 13(8):e1002067. PubMed ID: 27504960
[TBL] [Abstract][Full Text] [Related]
39. Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting.
Blohmer JU; Rezai M; Kümmel S; Kühn T; Warm M; Friedrichs K; Benkow A; Valentine WJ; Eiermann W
J Med Econ; 2013; 16(1):30-40. PubMed ID: 22966753
[TBL] [Abstract][Full Text] [Related]
40. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer.
Ragaz J; Jackson SM; Le N; Plenderleith IH; Spinelli JJ; Basco VE; Wilson KS; Knowling MA; Coppin CM; Paradis M; Coldman AJ; Olivotto IA
N Engl J Med; 1997 Oct; 337(14):956-62. PubMed ID: 9309100
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
